Whalesbook
Asal mein hua kya hai, Dr. Reddy's ne Canada mein apna generic Semaglutide Injection launch kar diya hai. Aur mazedaar baat yeh hai ki yeh pehli baar hua hai kisi G7 country mein! Health Canada ne is launch ko April 28, 2026 ko approve kiya tha. Yeh sab isliye possible ho paya kyunki Canada mein Novo Nordisk ke Ozempic ka ek zaroori patent miss ho gaya tha maintenance fees na bharne ki wajah se, jo 2018 se hi pending tha. Toh ab market mein Ozempic ka monopoly khatam ho gaya hai.
Dr. Reddy's, jinki market cap lagbhag $11.4 billion USD hai, ab Ozempic ka ek affordable alternative laane ke liye ready hai. Company ke CEO Erez Israeli ne kaha hai ki pricing "bahut healthy" rahegi, haalanki shuru mein thoda mehnga ho sakta hai kyunki abhi competition kam hai. Haal hi mein May 14, 2026 ko, company ka stock lagbhag ₹1,336.70 (yaani $16 USD ke aas paas) trade kar raha tha, jo apne 52-week range mein hi tha.
Yeh sab GLP-1 market ke liye bahut bada deal hai, jiska global market $190 billion tak pahunch sakta hai 2035 tak. Canada mein bhi $2.7 billion kharch ho rahe hain diabetes drugs par, jismein GLP-1 ka share 25% hai. Ozempic ne khud $2.9 billion ki sales ki thi Canada mein 2025 mein.
Novo Nordisk jo market leader hai 55.1% share ke saath, ab badi challenge face karegi. Kyunki Canada mein unka patent US se pehle hi khatam ho gaya hai. Eli Lilly jaise competitors bhi race mein hain. Canada mein generic drugs brand name se 45-90% tak saste milte hain. Dr. Reddy's ke baad ab Apotex ne bhi approval pa liya hai, aur 7 aur generic entries waiting mein hain.
Dr. Reddy's khud bhi financial growth dikha raha hai, jismein 14.4% CAGR tha FY2021 se FY2025 tak, aur operating margin bhi sudhar kar 22.4% ho gaya tha FY2025 mein.
Par haan, is competition mein price erosion ka risk hai, jo profit margins ko affect kar sakta hai. Analysts ki rai mili-juli hai, consensus rating "Hold" hai aur average target price $16.90 USD hai. Lekin, Goldman Sachs ne April 2026 mein Dr. Reddy's ko "Sell" rating de di thi generic Ozempic ko lekar concerns ke karan. MarketsMOJO ne bhi May 2026 mein "Hold" downgrade kiya tha. Halanki, company ka balance sheet mazboot hai aur debt bhi kam hai.
Company ko future growth ki umeed hai naye product launches se, jaise ki yeh generic Semaglutide aur arthritis drug Abatacept, jiska launch FY28 mein anticipated hai. India, Europe aur emerging markets se bhi growth expected hai. Canada mein demand zabardast hai, par Dr. Reddy's ko apni pricing strategy aur market share gain karne ki ability par focus karna hoga. Goldman Sachs ka "Sell" rating ek warning hai jo dhyan dene layak hai.